Literature DB >> 27170343

Melatonin reduces PERK-eIF2α-ATF4-mediated endoplasmic reticulum stress during myocardial ischemia-reperfusion injury: role of RISK and SAFE pathways interaction.

Liming Yu1, Buying Li1, Meng Zhang2, Zhenxiao Jin1, Weixun Duan1, Guolong Zhao3, Yang Yang4, Zhenhua Liu1, Wensheng Chen1, Siwang Wang2, Jian Yang1, Dinghua Yi1, Jincheng Liu5, Shiqiang Yu6.   

Abstract

Recently, we demonstrated that melatonin reduced protein kinase RNA (PKR)-like ER kinase (PERK)-eukaryotic initiation factor 2 alpha (eIF2α)-activating transcription factor-4 (ATF4)-mediated myocardial endoplasmic reticulum (ER) stress and apoptosis during myocardial ischemia-reperfusion (MI/R) injury. However, the underlying mechanisms are still not clear. Myocardial reperfusion injury salvage kinase (RISK) pathway as well as survivor activating factor enhancement (SAFE) pathway are two pivotal intrinsic pro-survival signaling cascades. In this study, we performed in vivo and in vitro experiment to investigate the ameliorative effect of melatonin on ER stress with a focus on RISK and SAFE pathways interaction. Male C57Bl/6 mice received melatonin (300 μg/25 g/day, 3 days before MI/R surgery; 300 μg/25 g, 25 min before the onset of ischemia) pre-treatment with or without the administration of LY294002 (a PI3K/Akt inhibitor), U0126 (an ERK1/2 inhibitor) or AG490 (a STAT3 pathway inhibitor). H9c2 cells were pre-treated with melatonin (100 μM, 8 h) in the presence or absence of LY294002, U0126 or AG490. Compared with the I/R-injured group, melatonin effectively reduced myocardial apoptosis, oxidative stress and improved cardiac function. In addition, melatonin pre-treatment also increased the phosphorylation of Akt, GSK-3β, ERK1/2 and STAT3 and reduced PERK-eIF2α-ATF4-mediated ER stress. However, these effects were blocked by LY294002, U0126 or AG490. Additionally, either LY294002 or U0126 treatment could inhibit STAT3 phosphorylation, whereas AG490 administration also reduced both Akt and ERK1/2 phosphorylation, indicating an interplay exists between RISK and SAFE pathways in melatonin's cardioprotective effect. In summary, our study demonstrates that RISK and SAFE pathways mediate the cardioprotective effect of melatonin against MI/R injury. Melatonin pre-treatment attenuates PERK-eIF2α-ATF4-mediated ER stress and apoptosis during MI/R injury via RISK and SAFE pathways interaction.

Entities:  

Keywords:  Endoplasmic reticulum stress; Melatonin; Myocardial ischemia–reperfusion injury; Reperfusion injury salvage kinase pathway; Survivor activating factor enhancement pathway

Mesh:

Substances:

Year:  2016        PMID: 27170343     DOI: 10.1007/s10495-016-1246-1

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  33 in total

1.  Naringenin ameliorates hypoxia/reoxygenation-induced endoplasmic reticulum stress-mediated apoptosis in H9c2 myocardial cells: involvement in ATF6, IRE1α and PERK signaling activation.

Authors:  Jia-You Tang; Ping Jin; Qing He; Lin-He Lu; Ji-Peng Ma; Wei-Lun Gao; He-Ping Bai; Jian Yang
Journal:  Mol Cell Biochem       Date:  2016-10-26       Impact factor: 3.396

2.  Therapeutic potential of a single-dose melatonin in the attenuation of cardiac ischemia/reperfusion injury in prediabetic obese rats.

Authors:  Kodchanan Singhanat; Nattayaporn Apaijai; Natticha Sumneang; Chayodom Maneechote; Busarin Arunsak; Titikorn Chunchai; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Cell Mol Life Sci       Date:  2022-05-19       Impact factor: 9.261

Review 3.  The integrated stress response in ischemic diseases.

Authors:  Guangyu Zhang; Xiaoding Wang; Beverly A Rothermel; Sergio Lavandero; Zhao V Wang
Journal:  Cell Death Differ       Date:  2021-11-06       Impact factor: 12.067

Review 4.  Melatonin as a protective agent in cardiac ischemia-reperfusion injury: Vision/Illusion?

Authors:  Puneet Kaur Randhawa; Manish Kumar Gupta
Journal:  Eur J Pharmacol       Date:  2020-08-26       Impact factor: 4.432

Review 5.  Melatonin: does it have utility in the treatment of haematological neoplasms?

Authors:  Tian Li; Zhi Yang; Shuai Jiang; Wencheng Di; Zhiqiang Ma; Wei Hu; Fulin Chen; Russel J Reiter; Yang Yang
Journal:  Br J Pharmacol       Date:  2017-09-09       Impact factor: 8.739

Review 6.  Roles of melatonin and its receptors in cardiac ischemia-reperfusion injury.

Authors:  Kodchanan Singhanat; Nattayaporn Apaijai; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Cell Mol Life Sci       Date:  2018-08-13       Impact factor: 9.261

Review 7.  Guidelines for evaluating myocardial cell death.

Authors:  Paras K Mishra; Adriana Adameova; Joseph A Hill; Christopher P Baines; Peter M Kang; James M Downey; Jagat Narula; Masafumi Takahashi; Antonio Abbate; Hande C Piristine; Sumit Kar; Shi Su; Jason K Higa; Nicholas K Kawasaki; Takashi Matsui
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-16       Impact factor: 4.733

8.  Melatonin ameliorates myocardial ischemia/reperfusion injury in type 1 diabetic rats by preserving mitochondrial function: role of AMPK-PGC-1α-SIRT3 signaling.

Authors:  Liming Yu; Bing Gong; Weixun Duan; Chongxi Fan; Jian Zhang; Zhi Li; Xiaodong Xue; Yinli Xu; Dandan Meng; Buying Li; Meng Zhang; Zhenxiao Jin; Shiqiang Yu; Yang Yang; Huishan Wang
Journal:  Sci Rep       Date:  2017-01-25       Impact factor: 4.379

Review 9.  Clinical Application of Melatonin in the Treatment of Cardiovascular Diseases: Current Evidence and New Insights into the Cardioprotective and Cardiotherapeutic Properties.

Authors:  Mohammad Hossein Pourhanifeh; Ehsan Dehdashtian; Azam Hosseinzadeh; Seyed Hashem Sezavar; Saeed Mehrzadi
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-14       Impact factor: 3.727

10.  Melatonin Mitigates Kainic Acid-Induced Neuronal Tau Hyperphosphorylation and Memory Deficits through Alleviating ER Stress.

Authors:  Cai Shi; Jia Zeng; Zixi Li; Qingjie Chen; Weijian Hang; Liangtao Xia; Yue Wu; Juan Chen; Anbing Shi
Journal:  Front Mol Neurosci       Date:  2018-01-24       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.